Théa's news

Thea x Sepulbio Théa

Sepul Bio, an innovative business unit of Théa, Doses First Participant in Phase 3 HYPERIONclinical trial of sepofarsen for CEP290-associated Leber Congenital Amaurosis Type 10

Sepul Bio: Théa’s Innovative Unit Doses First in Phase 3 HYPERION Trial for LCA10

10/1/25

Théa Opens a New Chapter in Retinal Diseases Pathology / Innovation

Théa Opens a New Chapter in Retinal Diseases

Théa Opens a New Chapter in Retinal Diseases

9/29/25

Nordics International

Official opening of the Stockholm office!

A new chapter for the Nordic region

8/28/25

Théa x Lenz Therapeutics Corporate

Licensing agreement between LENZ Therapeutics and Laboratoires Théa

New partnership Théa and Lenz Therapeutics

8/27/25

This year, ABAK® celebrating 30 years of innovation. Théa

This year, ABAK® celebrates its 30th anniversary!

This year, ABAK® celebrating 30 years of innovation.

8/27/25

New partnership: Théa and Pierre Fabre Corporate

Théa & Novaliq Launch Vevizye®

Théa and Novaliq announce their partnership.

8/27/25

Théa and Pierre Fabre announce their technological partnership. Corporate

Théa and Pierre Fabre announce their technological partnership.

Théa and Pierre Fabre announce their technological partnership.

8/27/25

Théa celebrates its 30th anniversary Corporate

Théa celebrates its 30th anniversary

Théa celebrates its 30 years: Innovation, Engagement, proximity and education.

4/29/25